LIPIMETIX DEVELOPMENT, INC. (LDI) CONTINGENT VALUE RIGHTS AGREEMENT ISSUED BY CAPSTONE THERAPEUTICS CORP. BY AND AMONG CAPSTONE THERAPEUTICS CORP. THE SHAREHOLDER REPRESENTATIVE, AS DEFINED HEREIN AND COMPUTERSHARE INC. AND COMPUTERSHARE TRUST...Contingent Value Rights Agreement • August 26th, 2019 • Capstone Therapeutics Corp. • Pharmaceutical preparations • Delaware
THIS LDI CONTINGENT VALUE RIGHTS AGREEMENT, (this “Agreement”) dated as of August 23, 2019 (the “Effective Date”), is entered into by and among Capstone Therapeutics Corp., a Delaware corporation (the “Company”), Computershare Inc. (“Computershare”) and its wholly owned subsidiary, Computershare Trust Company, N.A. together as rights agent (the “Rights Agent”) and the Shareholder Representative.
tHIRD AMENDMENT TO SECURITIES PURCHASE, LOAN AND SECURITY AGREEMENTSecurities Purchase, Loan and Security Agreement • August 26th, 2019 • Capstone Therapeutics Corp. • Pharmaceutical preparations
THIS THIRD AMENDMENT TO SECURITIES PURCHASE, LOAN AND SECURITY AGREEMENT (the “Amendment”) is made as of the 23rd day of August, 2019 by and between Capstone Therapeutics Corp., a Delaware corporation located at 1275 West Washington Street, Suite 104, Tempe, Arizona 85281 (the “Company”), and BP Peptides, LLC, a Delaware limited liability company located at 232 Madison Avenue, Suite 600, New York, New York 10016 (the “Buyer”).
